(2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one
• 化学式: C₅₂H₇₆O₂₄
• 分子量: 1085.1
• InChiKey: CFCUWKMKBJTWLW-WZIVUMCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  76
• 可旋转键数：
  15
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  358
• 氢给体数：
  11
• 氢受体数：
  24

ADMET

毒理性

• 相互作用

普卡霉素引起的低凝血酶原血症可能会增加香豆素类和茚满二酮衍生物抗凝剂的活动性，并可能增加接受肝素或溶栓药物治疗的患者的出血风险；不推荐同时使用。

Plicamycin-induced hypoprothrombinemia may increase the activity of coumarin- and indandione-derivative anticoagulants and may increase the risk of bleeding in patient receiving heparin or thrombolytic agents; concurrent use is not recommended.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

同时使用非甾体抗炎药、阿司匹林、右旋糖酐、双嘧达莫、磺吡拉宗或丙戊酸与普卡霉素可能会增加出血风险，因为这些药物单独或与普卡霉素联合使用时，可能会通过增加或协同作用降低血液凝固能力，即抑制血小板聚集，同时普卡霉素和大剂量阿司匹林可能会诱导低凝血酶原血症；此外，阿司匹林、非甾体抗炎药或磺吡拉宗的胃肠道溃疡性或出血倾向可能会增加接受普卡霉素治疗患者的出血风险。

Concurrent use /of nonsteroidal anti-inflammatory drugs, aspirin, dextran, dipyridamole, sulfinpyrazone, or valproic acid/ with plicamycin may increase the risk of hemorrhage because of additive or multiple actions, which may decrease the blood-clotting ability, ie, inhibition of platelet aggregation, by these medications and/or plicamycin combined with induction of hypoprothrombinemia by plicamycin and large dose of aspirin; in addition, the gastrointestinal ulcerative or hemorrhagic potential of aspirin, the nonsteroidal anti-inflammatory drugs, or sulfinpyrazone may increase the risk of hemorrhage in plicamycin-treated patients.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用